IQVIA (NYSE:IQV) Price Target Lowered to $250.00 at The Goldman Sachs Group

IQVIA (NYSE:IQV) had its price objective decreased by The Goldman Sachs Group from $280.00 to $250.00 in a research report released on Friday morning, Benzinga reports. The Goldman Sachs Group currently has a buy rating on the medical research company’s stock.

A number of other equities analysts have also weighed in on IQV. Redburn Atlantic initiated coverage on shares of IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 price target on the stock. Argus upgraded IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Royal Bank of Canada initiated coverage on IQVIA in a research note on Wednesday, September 4th. They issued an “outperform” rating and a $275.00 price objective on the stock. Morgan Stanley raised their price target on shares of IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, July 23rd. Finally, Jefferies Financial Group downgraded shares of IQVIA from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $266.00 to $242.00 in a research note on Wednesday, July 24th. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $261.56.

IQVIA Stock Performance

NYSE IQV opened at $210.19 on Friday. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The company has a market capitalization of $38.15 billion, a PE ratio of 27.58, a price-to-earnings-growth ratio of 2.07 and a beta of 1.51. The business’s 50-day moving average price is $233.55 and its 200 day moving average price is $229.64. IQVIA has a twelve month low of $190.20 and a twelve month high of $261.73.

Insider Activity

In related news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now directly owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On IQVIA

A number of institutional investors have recently modified their holdings of the stock. First Foundation Advisors lifted its position in shares of IQVIA by 3.8% in the 2nd quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock worth $245,000 after buying an additional 43 shares during the last quarter. Team Hewins LLC boosted its stake in IQVIA by 5.0% in the first quarter. Team Hewins LLC now owns 973 shares of the medical research company’s stock valued at $246,000 after acquiring an additional 46 shares during the period. Invera Wealth Advisors LLC grew its holdings in shares of IQVIA by 0.3% during the second quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock valued at $3,183,000 after purchasing an additional 46 shares during the last quarter. Covestor Ltd raised its position in shares of IQVIA by 45.3% during the 1st quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock worth $39,000 after purchasing an additional 48 shares during the period. Finally, Oregon Public Employees Retirement Fund lifted its holdings in shares of IQVIA by 0.3% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock worth $3,313,000 after purchasing an additional 48 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.